Follow on Google News News By Tag * Ophthalmology * Ophthalmology Therapeutics * Ophthalmology Markets * Glaucoma * Allergic Conjunctivitis * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016Ophthalmology Markets Like Glaucoma Face Generic Erosion While Macular Degeneration and Edema Experience Healthy Growth
By: GBI Research For more information please click or add the below link to your browser: http://www.gbiresearch.com/ The entry of generics will cause glaucoma’s market share to shrink. The macular degeneration and macular edema markets will eat into glaucoma’s share. The share of the market generated by allergic conjunctivitis therapies, which includes a considerable number of generics, will remain the same in 2016. Due to the extensive presence of generics in the market, allergic conjunctivitis companies will take steps to improve the revenue potential of their drugs. The Rx to OTC switch is one of the strategies that can be leveraged at the right time to increase revenue potential. In addition, strategies such as branded generics will be increasingly used in the ophthalmology market. GBI Research finds the global ophthalmology market is facing changes such as low treatment seeking and diagnosis rates which will result in huge untapped opportunities in the market. This untapped market can be accessed by companies only if the treatment seeking and diagnosis rates for indications such as dy macular degeneration improve. Diagnosis is at times delayed despite effective tests available in the market. Encouraging early detection of ophthalmic diseases by increasing physician and patient awareness is important. The treatment usage pattern for 2009 suggests that approximately 123 million people did not seek treatment, were improperly diagnosed or lost to alternative care or other options during the course of treatment. The focus on a greater understanding of the disease and on early detection will help to improve the treatment seeking rate in the market. The ophthalmology market pipeline has a considerable number of products that focus on novel therapies. Some of the therapies are first-in-class and these will have the biggest impact on the market in the coming years. The market for dry macular degeneration and early stage glaucoma presents huge opportunities. Diabetic retinopathy also holds the potential for market expansion as many companies are interested in exploiting this market which has no approved products. GBI Research’s report, “The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets”, provides in-depth analysis of the unmet needs, drivers and barriers that impact the global ophthalmology therapeutics market. The report analyzes the ophthalmology markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive profiling for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. For more information please click or add the below link to your browser: http://www.gbiresearch.com/ Visit our report store: http://www.gbiresearch.com # # # GBI Research is a global market intelligence services company providing information research and analysis products and services. End
|
|